Lymphoma Immunotherapy: Current Status
The rationale to treat lymphomas with immunotherapy comes from long-standing evidence on their distinctive immune responsiveness. Indolent B-cell non-Hodgkin lymphomas, in particular, establish key interactions with the immune microenvironment to ensure prosurvival signals and prevent antitumor immu...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555084/ |